Literature DB >> 9052636

Serine-27-phenylalanine mutation within the peripherin/RDS gene in a family with cone dystrophy.

G A Fishman1, E M Stone, K R Alexander, L D Gilbert, D J Derlacki, N S Butler.   

Abstract

PURPOSE: To evaluate the clinical and electrophysiologic findings in a family with two heterozygous sequence changes in the peripherin-retinal degeneration slow (RDS) gene.
METHODS: A family study was done of a pedigree obtained by screening for rhodopsin, peripherin/RDS, or rom-1 gene mutations in probands from families with hereditary retinal diseases. The patients consisted of three affected and four unaffected members from a family with cone dystrophy. Ophthalmoscopy, visual field testing, electroretinography, and DNA analysis were performed.
RESULTS: Denaturing gradient gel electrophoresis showed the presence of two different sequence changes in the RDS genes of this family. In three members with a retinal disease, the authors observed the substitution of phenylalanine for serine in codon 27 (serine-27-phenylalanine). The clinical and functional findings in these three patients were most consistent with autosomal-dominant cone dystrophy. Three other family members, unaffected with retinal disease, were found to show a substitution of serine for cysteine in codon 72 of the peripherin protein.
CONCLUSION: A peripherin/RDS sequence change may produce a cone dystrophy with minimal ophthalmoscopic changes in the macula and limited peripheral degenerative changes. Caution is warranted to avoid ascribing nondisease-causing sequence polymorphisms in candidate genes as responsible for determining the development of a retinal disease phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052636     DOI: 10.1016/s0161-6420(97)30320-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  A novel CRX mutation by whole-exome sequencing in an autosomal dominant cone-rod dystrophy pedigree.

Authors:  Qin-Kang Lu; Na Zhao; Ya-Su Lv; Wei-Kun Gong; Hui-Yun Wang; Qi-Hu Tong; Xiao-Ming Lai; Rong-Rong Liu; Ming-Yan Fang; Jian-Guo Zhang; Zhen-Fang Du; Xian-Ning Zhang
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

2.  Genetic supplementation of RDS alleviates a loss-of-function phenotype in C214S model of retinitis pigmentosa.

Authors:  May Nour; Steven J Fliesler; Muna I Naash
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  Intrafamilial phenotypic variability in families with RDS mutations: exclusion of ROM1 as a genetic modifier for those with retinitis pigmentosa.

Authors:  B P Leroy; A Kailasanathan; J-J De Laey; G C M Black; F D C Manson
Journal:  Br J Ophthalmol       Date:  2006-08-17       Impact factor: 4.638

4.  Progressive cone dystrophy with deutan genotype and phenotype.

Authors:  Hendrik P N Scholl; Jan Kremers; Dorothea Besch; Eberhart Zrenner; Herbert Jägle
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-05       Impact factor: 3.117

5.  PRPH2 mutation update: In silico assessment of 245 reported and 7 novel variants in patients with retinal disease.

Authors:  Manon H C A Peeters; Mubeen Khan; Anoek A M B Rooijakkers; Timo Mulders; Lonneke Haer-Wigman; Camiel J F Boon; Caroline C W Klaver; L Ingeborgh van den Born; Carel B Hoyng; Frans P M Cremers; Anneke I den Hollander; Claire-Marie Dhaenens; Rob W J Collin
Journal:  Hum Mutat       Date:  2021-09-20       Impact factor: 4.700

6.  ERGs, cone-isolating VEPs and analytical techniques in children with cone dysfunction syndromes.

Authors:  John P Kelly; Michael A Crognale; Avery H Weiss
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

7.  Exome sequencing of 47 chinese families with cone-rod dystrophy: mutations in 25 known causative genes.

Authors:  Li Huang; Qingyan Zhang; Shiqiang Li; Liping Guan; Xueshan Xiao; Jianguo Zhang; Xiaoyun Jia; Wenmin Sun; Zhihong Zhu; Yang Gao; Ye Yin; Panfeng Wang; Xiangming Guo; Jun Wang; Qingjiong Zhang
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.